S&P 500 Rises 100 Points; Nasdaq Up 3%
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite climbing more than 300 points on Tuesday.
Nasdaq Surges 250 Points; Crude Oil Rises Sharply
U.S. stocks traded higher midway through trading, with the Nasdaq Composite climbing more than 250 points on Tuesday.
RBC Says Verastem Interim Analysis In Ovarian Cancer Reinforces Enthusiasm
With the anticipation of a 2Q program update, Verastem Oncology (NASDAQ:VSTM) announced that its interim analysis findings for the RAMP 201 program…
Verastem Oncology’s Return On Capital Employed Insights
Verastem Oncology (NASDAQ:VSTM) brought in sales totaling $2.60 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 2.92%, resulting in a loss of $16.96 million.
FDA Puts Blood Cancer Nods Under Scrutiny On Substantial Toxicity Profile Of PI3K Drugs
The FDA aims to put the PI3K inhibitor drug class under a more stringent regulatory scope as the inhibitor has demonstrated substantial toxicity.
RBC Capital Initiates Coverage On Verastem with Outperform Rating, Announces Price Target of $5
RBC Capital analyst Gregory Renza initiates coverage on Verastem (NASDAQ:VSTM) with a Outperform rating and announces Price Target of $5.
Verastem Oncology’s Return On Capital Employed Insights
According to data from Benzinga Pro, during Q4, Verastem Oncology's (NASDAQ:VSTM) reported sales totaled $545.00 thousand. Despite a 27.67% increase in earnings, the company posted a loss of $16.48 million.